

PRV

PATENT- OCH REGISTRERINGSVERKET
Patentavdelningen

PCT / SE 2004 / 001590

**Intyg
Certificate**

REC'D 16 NOV 2004

WIPO PCT

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

Ansökan ingavs ursprungligen på engelska.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

The application was originally filed in English.

(71) Sökande AstraZeneca AB, Södertälje SE
Applicant (s)

(21) Patentansökningsnummer 0302956-8
Patent application number

(86) Ingivningsdatum 2003-11-07
Date of filing

Stockholm, 2004-09-15

För Patent- och registreringsverket
For the Patent- and Registration Office

Hjördis Segerlund
Hjördis Segerlund

Avgift
Fee 170:-

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

**PATENT- OCH
REGISTRERINGSVERKET
SWEDEN**

Postadress/Adress
Box 5055
S-102 42 STOCKHOLM

Telefon/Phone
+46 8 782 25 00
Vx 08-782 25 00


Telex
17978
PATOREG S

Telefax
+46 8 666 02 86
08-666 02 86

CHEMICAL COMPOUNDS

The present invention concerns forms of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide, and hydrates and anhydrous forms of its sodium salt, to processes for preparing such forms, to pharmaceutical compositions comprising such a form, and to the use of such a form as an active therapeutic agent in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.

N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide:



and its sodium salt are disclosed in Example 10A of WO 03/004487. In Example 10A of WO 03/004487 the mono-sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide is disclosed as an anhydrous form (hereinafter called Anhydrous Form A).

It has now surprisingly been found that there are two further anhydrous forms (Anhydrous Form B and Anhydrous Form C) of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide.

Thus, the present invention provides an anhydrous form of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide Anhydrous Form B having an X-ray powder diffraction pattern containing specific peaks at: 3.8° (±0.1°), 7.5° (±0.1°), 20.2° (±0.2°) and 22.5° (±0.1°) 2θ.

Thus, the present invention also provides an anhydrous form of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide Anhydrous Form C having an X-ray powder diffraction pattern containing specific peaks at: 4.4° (±0.1°), 8.3° (±0.1°), 14.5° (±0.1°), 16.6° (±0.1°), 20.2° (±0.1°), 21.1° (±0.1°) and 22.0° (±0.1°) 2θ.

It has now surprisingly also been found that there are three hydrated forms (Hydrate Form A, Hydrate Form B and Hydrate Form C) of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide.

Thus, the present invention provides a hydrated form of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide Hydrate Form A having an X-ray powder diffraction pattern containing specific peaks at: 4.2° (±0.1°), 20.4° (±0.1°), 22.5° (±0.1°) and 23.2° (±0.1°) 2θ. In one particular aspect the present invention provides Hydrate Form A of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide wherein the water content is 3-8% w/w.

Thus, the present invention also provides a hydrated form of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide Hydrate Form B having an X-ray powder diffraction pattern (XRPD) containing specific peaks at: 4.5° (±0.1°), 8.3° (±0.1°), 14.5° (±0.1°), 16.6° (±0.1°), 20.2° (±0.1°), 21.9° (±0.1°) and 23.6° (±0.1°) 2θ. In one particular aspect the present invention provides Hydrate Form B of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide wherein the water content is 5-7% w/w.

Thus, the present invention also provides a hydrated form of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide Hydrate Form C having an X-ray powder diffraction pattern containing specific peaks at: 4.3° (±0.1°), 15.7° (±0.1°), 15.9° (±0.1°), 19.1° (±0.1°), 20.6° (±0.1°), and 21.1° (±0.1°) 2θ. In another aspect the present invention provides a hydrated form of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide Hydrate Form C having an X-ray powder diffraction pattern containing specific peaks at: 4.3° (±0.1°), 8.2° (±0.1°), 12.6° (±0.1°), 15.2° (±0.1°), 15.7° (±0.1°), 15.9° (±0.1°), 17.9° (±0.1°), 19.1° (±0.1°), 20.6° (±0.1°), 21.2° (±0.1°), 22.7° (±0.1°), and 24.7° (±0.1°) 2θ.

Further, it has now surprisingly been found that there are two polymorphic forms of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide (Form A and Form B).

Thus, the present invention provides *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide Form A having an X-ray powder diffraction

pattern containing specific peaks at: 15.5° ($\pm 0.1^\circ$), 15.9° ($\pm 0.1^\circ$), 19.9° ($\pm 0.1^\circ$), 20.2° ($\pm 0.1^\circ$), 21.7° ($\pm 0.1^\circ$), 25.8° ($\pm 0.1^\circ$) and 26.6° ($\pm 0.1^\circ$) 2 θ .

Thus, the present invention also provides *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide Form B having an X-ray powder diffraction pattern containing specific peaks at: 11.0° ($\pm 0.1^\circ$), 11.6° ($\pm 0.1^\circ$), 13.3° ($\pm 0.1^\circ$), 14.9° ($\pm 0.1^\circ$), 18.0° ($\pm 0.1^\circ$), 19.0° ($\pm 0.1^\circ$), 20.3° ($\pm 0.1^\circ$), 22.21° ($\pm 0.1^\circ$), 23.01° ($\pm 0.1^\circ$) and 23.21° ($\pm 0.1^\circ$) 2 θ .

The Anhydrous Form B of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide can be prepared as follows. 4-(3,4-Dichlorophenoxy)-1,4'-bipiperidine is reacted with 4-methylbenzenesulfonyl isocyanate in a suitable solvent (for example dichloromethane) keeping the temperature below 30°C (for example at a temperature in the range 10-30°C). Solid *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide forms and is separated and then dissolved in aqueous sodium hydroxide. The aqueous solution is extracted with a suitable organic solvent (for example dichloromethane), the organic extracts are combined, the volume of solvent reduced and sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide crystallises from solution. The salt may be recrystallised from ethanol-water. The salt is suspended in aqueous sodium hydroxide and dichloromethane, the organic layer is separated and filtered to leave a residue which is triturated with water and then dried in the presence of phosphorus pentoxide under reduced pressure (such as below 50mm Hg), for example at a temperature in the range 20-60°C.

Alternatively, the Anhydrous Form B of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide can be prepared by taking the Hydrate Form A of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide and drying it in the presence of phosphorus pentoxide under reduced pressure (such as below 50mm Hg), for example at a temperature in the range 20-60°C.

Alternatively, the Anhydrous Form B of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide can be prepared by taking the Hydrate Form A of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide and

heating it from ambient (that is room) temperature to 100°C, for example under an atmosphere of nitrogen.

The Anhydrous Form C of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)-[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide can be prepared by taking the Hydrate Form B of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide and heating it from ambient (that is room) temperature to 100°C, for example under an atmosphere of nitrogen.

The Hydrate Form A of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide can be prepared as follows. 4-(3,4-Dichlorophenoxy)-1,4'-bipiperidine is reacted with 4-methylbenzenesulfonyl isocyanate in a suitable solvent (for example tetrahydrofuran) at ambient temperature (such as a temperature in the range 10-30°C) to form *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide in the suitable solvent; and:

- a. concentrated aqueous sodium hydroxide solution (for example 8-12N) is added followed by water. The resulting mixture may then be stirred to allow crude Hydrate Form A of the sodium salt, possibly contaminated with suitable solvent, to precipitate out (said crude product can be recrystallised from water), or, alternatively, the suitable solvent can be distilled off and the desired Hydrate Form A of the sodium salt allowed to precipitate from the aqueous; OR,
- b. water is added and *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide precipitates. The *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide is mixed with water, heated to a temperature in the range 30-60°C, concentrated aqueous sodium hydroxide solution (for example 8-12N) is added and the mixture cooled with the Hydrate Form A of the sodium salt precipitating.

Alternatively, the Hydrate Form A of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide can be prepared by mixing *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide Form B and aqueous sodium hydroxide, heating the mixture (such as to 40-60°C) and then extracting the cooled mixture with dichloromethane. The volume of solvent of combined organic extracts may be reduced and the extracts are cooled (such as to -10 to 10°C) for example with stirring and Hydrate Form A precipitates from

solution. Hydrate Form A may be dried under reduced pressure (for example below 50mm Hg) at 30-50°C.

The Hydrate Form B of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide can be prepared by mixing a solution of 4-(3,4-dichlorophenoxy)-1,4'-bipiperidine in tetrahydrofuran with a solution of 4-methylbenzenesulfonyl isocyanate in tetrahydrofuran at a temperature in the range 15-35°C. Aqueous sodium hydroxide solution (such as concentrated (for example 10N), and one equivalent) is added and the Hydrate Form B precipitates from the reaction mixture.

The Hydrate Form C of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide can be prepared by dissolving the mono-sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide in a mixture of water and acetone (for example in the v/v ratio of about 1:4) at reflux and allowing the solution to cool to room temperature and then cooling it to around 0°C. The Hydrate Form C crystallises from solution during the cooling.

N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide Form A can be prepared by crystallising *N*-[[4-(3,4-dichlorophenoxy)-[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide from ethanol and then purifying the crystallised product using reverse phase chromatography eluting with a mixture of aqueous ammonia and acetonitrile. The desired fractions are combined, freeze dried and the residue triturated with acetonitrile and the dried under reduced pressure at ambient temperature (10 to 30°C).

Alternatively, *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide Form A can be prepared by mixing *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide Form B and acetonitrile and heating the mixture to 40-60°C. The solid from the slurry so formed is dried under reduced pressure, for example at a temperature in the range 30 to 50°C.

N-[[4-(3,4-Dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide Form B can be prepared by mixing 4-methylbenzenesulfonyl isocyanate and 4-(3,4-dichlorophenoxy)-1,4'-bipiperidine in dichloromethane. The mixture is stirred. Then:

1. Water is added. The organic layer is separated and allowed to stand and product crystallises from solution. The solid is collected and can be dried under reduced

pressure (such as below 50mm Hg) for example at a temperature in the range 30-50°C.

OR,

2. Solid precipitates from solution. The solid may be washed with dichloromethane.

5 The solid is dried under reduced pressure (such as below 50mm Hg) for example at a temperature in the range 30-50°C.

In further aspects the present invention provides processes for the preparation of the compounds of the invention.

10 The compounds of the invention have activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially CCR3) activity, and may be used in the treatment of autoimmune, inflammatory, proliferative or hyperproliferative diseases, or immunologically-mediated diseases (including rejection of transplanted organs or tissues and Acquired Immunodeficiency Syndrome (AIDS)).

Examples of these conditions are:

- 15 (1) (the respiratory tract) obstructive diseases of airways including: chronic obstructive pulmonary disease (COPD) (such as irreversible COPD); asthma (such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)); bronchitis (such as eosinophilic bronchitis); acute, allergic, atrophic rhinitis or chronic rhinitis including
20 rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis; sarcoidosis; farmer's lung and related diseases; nasal polyposis; fibroid lung, idiopathic interstitial pneumonia, antitussive activity, treatment of chronic cough associated with inflammatory conditions of the
25 airways or iatrogenic induced cough;
- (2) (bone and joints) arthrides including rheumatic, infectious, autoimmune, seronegative spondyloarthropathies (such as ankylosing spondylitis, psoriatic arthritis or Reiter's disease), Behçet's disease, Sjögren's syndrome or systemic sclerosis;
- 30 (3) (skin and eyes) psoriasis, atopic dermatitis, contact dermatitis or other eczematous dermatides, seborrhoetic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides erythemas, cutaneous eosinophilias, uveitis, Alopecia areata or vernal conjunctivitis;

- (4) (gastrointestinal tract) Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, irritable bowel disease or food-related allergies which have effects remote from the gut (for example migraine, rhinitis or eczema);
- 5 (5) (Allograft rejection) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea; or chronic graft versus host disease; and/or
- 10 (6) (other tissues or diseases) Alzheimer's disease, multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), Lupus disorders (such as lupus erythematosus or systemic lupus), erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, leprosy (such as lepromatous leprosy), Peridontal disease, Sezary syndrome, idiopathic thrombocytopenia pupura or disorders of the menstrual cycle.

The compounds of the invention are also H1 antagonists and may be used in the
15 treatment of allergic disorders.

The compounds of the invention may also be used to control a sign and/or symptom of what is commonly referred to as a cold (for example a sign and/or symptom of a common cold or influenza or other associated respiratory virus infection).

20 According to a further feature of the invention there is provided a compound of the invention for use in a method of treatment of a warm blooded animal (such as man) by therapy (including prophylaxis).

25 According to a further feature of the present invention there is provided a method for modulating chemokine receptor activity (especially CCR3 receptor activity), or antagonising H1, in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of the invention.

The invention also provides a compound of the invention for use as a medicament.

30 In another aspect the invention provides the use of a compound of the invention in the manufacture of a medicament for use in therapy (for example modulating chemokine receptor activity (especially CCR3 receptor activity), or antagonising H1, in a warm blooded animal, such as man).

The invention further provides the use of a compound of the invention in the manufacture of a medicament for use in the treatment of:

- (1) (the respiratory tract) obstructive diseases of airways including: chronic obstructive pulmonary disease (COPD) (such as irreversible COPD); asthma {such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)}; bronchitis {such as eosinophilic bronchitis}; acute, allergic, atrophic rhinitis or chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis; sarcoidosis; farmer's lung and related diseases; nasal polyposis; fibroid lung, idiopathic interstitial pneumonia, antitussive activity, treatment of chronic cough associated with inflammatory conditions of the airways or iatrogenic induced cough;
- (2) (bone and joints) arthrides including rheumatic, infectious, autoimmune, seronegative spondyloarthropathies (such as ankylosing spondylitis, psoriatic arthritis or Reiter's disease), Behcet's disease, Sjogren's syndrome or systemic sclérosis;
- (3) (skin and eyes) psoriasis, atopic dermatitis, contact dermatitis or other eczematous dermatides, seborrhoetic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides erythemas, cutaneous eosinophilias, uveitis, Alopecia areata or vernal conjunctivitis;
- (4) (gastrointestinal tract) Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, irritable bowel disease or food-related allergies which have effects remote from the gut (for example migraine, rhinitis or eczema);
- (5) (Allograft rejection) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea; or chronic graft versus host disease; and/or
- (6) (other tissues or diseases) Alzheimer's disease, multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), Lupus disorders (such as lupus erythematosus or systemic lupus), erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, leprosy (such as lepromatous leprosy), Peridontal disease, sezary syndrome, idiopathic thrombocytopenia pupura or disorders of the menstrual cycle;
- (7) H1 antagonists and may be used in the treatment of allergic disorders; or,

(8) to control a sign and/or symptom of what is commonly referred to as a cold (for example a sign and/or symptom of a common cold or influenza or other associated respiratory virus infection);

in a warm blooded animal, such as man.

5 In a further aspect a compound of the invention is useful in the treatment of asthma {such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)); or rhinitis {including acute, allergic, atrophic or chronic rhinitis, such as rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa;
10 membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis}.

In a still further aspect a compound of the invention is useful in the treatment of asthma.

15 The present invention also provides the use of a compound of the invention in the manufacture of a medicament for use in the treatment of asthma or rhinitis.

The present invention further provides a method of treating a chemokine mediated disease state (especially a CCR3 mediated disease state, especially asthma) in a warm blooded animal, such as man, which comprises administering to a mammal in need of such
20 treatment an effective amount of a compound of the invention.

In order to use a compound of the invention for the therapeutic treatment of a warm blooded animal, such as man, in particular modulating chemokine receptor (for example CCR3 receptor) activity or antagonising H1, said compound is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

25 Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the invention and a pharmaceutically acceptable adjuvant, diluent or carrier. In a further aspect the present invention provides a process for the preparation of said composition which comprises mixing a compound of the invention with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending
30 on the mode of administration, the pharmaceutical composition may comprise from 0.05 to 99 %w (per cent by weight), such as from 0.05 to 80 %w, for example from 0.10 to 70 %w, or from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

The pharmaceutical compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by topical (such as to the lung and/or airways or to the skin), oral, rectal or parenteral administration. For these purposes the compounds of this invention may be formulated by means known in the art into the form of, for example, aerosols, dry powder formulations, tablets, capsules, syrups, powders, granules, aqueous or oily solutions or suspensions, (lipid) emulsions, dispersible powders, suppositories, ointments, creams, drops and sterile injectable aqueous or oily solutions or suspensions.

A suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule which contains between 0.1mg and 1g of a compound of the invention.

In another aspect a pharmaceutical composition of the invention is one suitable for intravenous, subcutaneous or intramuscular injection.

Each patient may receive, for example, an intravenous, subcutaneous or intramuscular dose of 0.01mgkg^{-1} to 100mgkg^{-1} of the compound, preferably in the range of 0.1mgkg^{-1} to 20mgkg^{-1} of this invention, the composition being administered 1 to 4 times per day. The intravenous, subcutaneous and intramuscular dose may be given by means of a bolus injection. Alternatively the intravenous dose may be given by continuous infusion over a period of time. Alternatively each patient will receive a daily oral dose which is approximately equivalent to the daily parenteral dose, the composition being administered 1 to 4 times per day.

The following illustrates a representative pharmaceutical dosage form containing a compound of the invention (Compound X), for therapeutic or prophylactic use in humans:

<u>Capsule</u>	<u>mg/capsule</u>
Compound X	10
Lactose Ph.Eur.	389
Croscarmellose sodium	100
Magnesium stearate	1.0

Buffers, pharmaceutically-acceptable cosolvents such as polyethylene glycol, polypropylene glycol, glycerol or ethanol or complexing agents such as hydroxy-propyl β -cyclodextrin may be used to aid formulation. The compositions of the invention can be

obtained by conventional procedures well known in the pharmaceutical art. Tablets may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.

The invention will now be illustrated by the following non-limiting Examples in which, unless stated otherwise:

(i) when given, ^1H NMR data is quoted and is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300MHz or 400MHz using perdeuterio DMSO-D6 (CD_3SOCD_3), methanol-D4 (CD_3OD) or CDCl_3 as the solvent unless otherwise stated;

(ii) mass spectra (MS) were run with an electron energy of 70 electron volts in the chemical ionisation (CI) mode using a direct exposure probe; where indicated ionisation was effected by electron impact (EI) or fast atom bombardment (FAB) or electrospray (ESI); where values for m/z are given, generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion -

(M+H) $^+$;

(iii) the title compounds of the Examples were named using the ACD/Ind \acute{e} x name program version 4.55 from Advanced Chemistry Development, Inc;

(iv) unless stated otherwise, reverse phase HPLC was conducted using a Symmetry, NovaPak or Xterra reverse phase silica column; and,

(v) the following abbreviations are used:

RPHPLC	reverse phase HPLC
XRPD	X-ray powder diffractometry
eq.	equivalents
aq	aqueous
DMSO	dimethylsulfoxide

THF	tetrahydrofuran
MeCN	acetonitrile
DCM	dichloromethane
m.pt.	melting point

METHODS

Method for X-Ray Powder Diffractometry (XRPD)

Analyses were performed on a Siemens model D5000 X-ray powder diffractometer using Copper K_α radiation ($\lambda=1.54056\text{\AA}$) fitted with a position sensitive detector (PSD). Samples (approximately 10mg) were dispensed as a thin powder layer on a silicon wafer zero-background holder. Reflections were collected between 2 and 40 $^\circ$ 2 θ at a step size of 0.007 $^\circ$ 2 θ and a step time of 1 or 2 seconds.

Method for thermogravimetric analysis (TGA)

The sample (approximately 5 mg) was dispensed onto the sample pan of a TA Instruments Model Q500 thermogravimetric analyser (TGA). The sample was heated from ambient temperature to 300°C under an atmosphere of nitrogen at a scan rate of 10°C min⁻¹.

EXAMPLE 1

This Example illustrates the preparation of the mono-sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide in Anhydrous Form B.

4-(3,4-Dichlorophenoxy)-1,4'-bipiperidine (20g) was dissolved in dichloromethane (150 ml). 4-Methylbenzenesulfonyl isocyanate (9.3ml) was added dropwise with cooling to maintain temperature <30°C. After 2 hours a solid was collected and washed with dichloromethane. The solid was dissolved in 0.25M aqueous sodium hydroxide (400 ml); this solution was extracted with dichloromethane thrice. The organic phases were combined and solvent partially evaporated to initiate crystallisation, then the product was allowed to crystallise. The solid was collected and recrystallised from ethanol/water (320ml, 30ml) and then dried in vacuo.

The resultant solid was suspended in 2M aqueous sodium hydroxide / dichloromethane (100ml of each); the dichloromethane layer was separated and filtered. The solid so collected was triturated with water, collected and then washed with dichloromethane. Drying in vacuo over P₂O₅ at 40°C gave the title compound.

m.pt. 229.5-231°C.

¹H NMR δ (CD₃OD): 1.36 (2H, qd), 1.70 - 1.83 (4H, m), 1.96 - 2.04 (2H, m), 2.35 (3H, s), 2.42 - 2.53 (3H, m), 2.56 - 2.66 (2H, m), 2.80 - 2.87 (2H, m), 4.32 - 4.44 (3H, m), 6.88 (1H, dd), 7.09 (1H, d), 7.21 (2H, d), 7.37 (1H, d), 7.77 (2H, d).

Karl Fischer analysis showed 0.26% water.

Contains 0.57% w/w moisture by TGA.

30 XRPD of the product is presented in Figure 1. XRPD main reflection peaks are:

Reflection angle (°2θ)	D-spacing (Å)	Relative intensity (%)
3.8	23.4	100

4.28	21.0	36
6.88	13.0	14
7.5	11.8	98
9.9	8.9	14
11.2	7.9	23
13.0	6.8	16
13.9	6.8	19
15.1	5.9	19
15.7	5.6	19
18.8	4.7	25
19.3	4.6	23
20.2	4.4	33
21.7	4.1	22
22.5	3.9	26
30.2	3.0	20

EXAMPLE 2

This Example illustrates the preparation of the mono-sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide in Anhydrous Form B.

Sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide Hydrate Form A (see Example 5; 2.63g, 4.36mmol) was dried *in vacuo* at 40°C in the presence of phosphorus pentoxide for 4 days to give the title material (2.30g, 4.19mmol).

10 MS [M+H]⁺ (EI) 526/528

¹H NMR δ (CD₃OD) 1.28 - 1.42 (2H, m), 1.70 - 1.82 (4H, m), 1.96 - 2.04 (2H, m), 2.35 (3H, s), 2.43 - 2.54 (3H, m), 2.56 - 2.66 (2H, m), 2.80 - 2.87 (2H, m), 4.34 - 4.42 (3H, m), 6.87 - 6.90 (1H, m), 7.09 - 7.10 (1H, m), 7.19 - 7.23 (2H, m), 7.35 - 7.38 (1H, m), 7.75 - 7.79 (2H, m).

15 ¹³C NMR δ (CD₃OD) 21.4, 29.3, 31.6, 43.2, 47.2, 63.8, 74.5, 117.3, 119.1, 124.7, 128.0, 129.7, 132.1, 133.8, 142.0, 144.0, 158.3, 162.8.

Example 3

This Example illustrates the preparation of the mono-sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide in Anhydrous Form B.

- 5 Sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide Hydrate Form A (see Example 5; approximately 10mg) was dispensed onto the sample pan of a TA Instruments Model Q500 thermogravimetric analyser (TGA). The sample was heated from ambient temperature to 100°C under an atmosphere of nitrogen at a scan rate of 10°C min⁻¹. The dried material produced was
10 allowed to cool under ambient laboratory conditions prior to XRPD analysis. Contains 0.22% w/w moisture by TGA

XRPD of the product is presented in Figure 2. XRPD main reflection peaks are:

Reflection angle (°2θ)	D-spacing (Å)	Relative intensity (%)
3.8	23.3	100
7.5	11.7	64
9.9	8.9	28
11.3	7.8	28
13.1	6.8	32
13.9	6.4	37
15.2	5.8	48
15.8	5.6	46
19.4	4.6	56
20.3	4.4	71
21.8	4.1	46
22.6	3.9	47

EXAMPLE 4

- 15 This Example illustrates the preparation of the mono-sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide in Anhydrous Form C.

Sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide Hydrate Form B (see Example 10; approximately 10mg) was

dispensed onto the sample pan of a TA Instruments Model Q500 thermogravimetric analyser (TGA). The sample was heated from ambient temperature to 100°C under an atmosphere of nitrogen at a scan rate of 10°C min⁻¹. The dried material produced was allowed to cool under ambient laboratory conditions prior to XRPD analysis.

5 No mass loss detected by TGA

XRPD of the product is presented in Figure 3. XRPD main reflection peaks are:

Reflection angle (°2θ)	D-spacing (Å)	Relative intensity (%)
4.4	20.0	100
5.3	16.8	37
8.3	10.7	56
14.5	6.1	40
14.7	6.0	38
15.3	5.8	34
16.6	5.4	43
18.7	4.8	30
19.5	4.6	32
20.2	4.4	49
21.1	4.2	49
21.5	4.1	35
22.0	4.0	42
22.3	4.0	33
23.3	3.8	34
23.5	3.8	35
25.0	3.6	31
26.7	3.3	29
27.2	3.3	29
29.2	3.1	28

EXAMPLE 5

10 This Example illustrates the preparation of the mono-sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide as Hydrate Form A.

To *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide Form B (see Example 13; 8.8g, 16.7mmol) was added 2M aqueous sodium hydroxide (25ml) and water (50ml). The suspension was heated to 50°C to give a solution. The solution was cooled and extracted with DCM (3 x 50ml). Solvent (70ml) was stripped from the combined organic fraction and the remaining solution stirred at 5°C which caused precipitation. Further DCM (50ml) was added to aid stirring. The slurry was filtered, washed with DCM (20ml) and dried *in vacuo* at 40°C to give the title compound.

m.pt. 240°C.

MS $[M+H]^+$ (EI) 526/528

^1H NMR δ (CD_3OD) 1.28 - 1.42 (2H, m), 1.70 - 1.82 (4H, m), 1.96 - 2.04 (2H, m), 2.35 (3H, s), 2.43 - 2.54 (3H, m), 2.56 - 2.66 (2H, m), 2.80 - 2.87 (2H, m), 4.34 - 4.42 (3H, m), 6.87 - 6.90 (1H, m), 7.09 - 7.10 (1H, m), 7.19 - 7.23 (2H, m), 7.35 - 7.38 (1H, m), 7.75 - 7.79 (2H, m). There is a large water peak at 4.87.

^{13}C NMR δ (CD_3OD) 21.4, 29.3, 31.6, 43.2, 47.2, 63.8, 74.5, 117.3, 119.1, 124.7, 128.0, 129.7, 132.1, 133.8, 142.0, 144.0, 158.3, 162.8

Contains 8.80% w/w moisture by TGA; 9.3% w/w water content by Karl Fischer analysis.

XRPD of the product is presented in Figure 4. XRPD main reflection peaks are:

Reflection angle (2θ)	D-spacing (\AA)	Relative intensity (%)
4.2	21.0	100
12.7	7.0	72
14.8	6.0	30
15.5	5.7	28
16.6	5.4	35
17.4	5.1	31
17.7	5.0	28
18.2	4.9	29
20.4	4.3	63
21.3	4.2	29
22.1	4.0	28
22.5	4.0	36

23.2	3.8	79
23.9	3.7	29
25.0	3.6	28
25.1	3.6	28
28.6	3.1	30
29.1	3.1	36
29.8	3.0	34
30.7	2.9	28

EXAMPLE 6

This Example illustrates the preparation of the mono-sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide as

5 Hydrate Form A.

To a solution of 4-(3,4-dichlorophenoxy)-1,4'-bipiperidine (60g) in THF (600ml) under N₂ at 25°C was added dropwise a solution of 4-methylbenzenesulfonyl isocyanate (28.43ml) in THF (250ml) and the reaction stirred under N₂ at 25°C for 45 minutes. 10M Aqueous sodium hydroxide (18.8ml) was added followed immediately by the addition of
10 water (40ml). After stirring for 24 hours the precipitate was filtered to give the crude material (73.8g). To the crude material (10g) was added water (50ml) and the mixture heated to 60°C, giving dissolution of the solid. The solution was cooled to 35°C and stirred for 4 hours, giving precipitation, and then cooled to 20°C and stirred for 20 hours. The precipitate was filtered to give a solid. This was dried (30°C, 10mbar) to give the title
15 compound (9.16g).

NMR data consistent with Example 5.

Contains 8.3% w/w moisture by TGA.

EXAMPLE 7

20 This Example illustrates the preparation of the mono-sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide as Hydrate Form A.

To a solution of 4-(3,4-dichlorophenoxy)-1,4'-bipiperidine (5g) in THF (50ml) under N₂ at 25°C was added 4-methylbenzenesulfonyl isocyanate (2.32ml) in THF (20ml)
25 dropwise and the reaction stirred under N₂ at 25°C for 3 hours. Water (14ml) was added

and the reaction stirred for 18 hours. The precipitate was now filtered to give *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide as a solid. To the solid was added water (30ml) and the mixture heated to 40°C. 10M Aqueous sodium hydroxide, (1.52ml) was now added and the reaction cooled to 35°C giving a precipitate. The mixture was stirred for 20 hours and then the precipitate was filtered. The solid was dried (30°C, 10mbar) to give the title compound (7.31g).

NMR data consistent with the Example 5

Contains 8.7% w/w moisture by TGA.

10

EXAMPLE 8

This Example illustrates the preparation of the mono-sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide as Hydrate Form A.

To a solution of 4-(3,4-dichlorophenoxy)-1,4'-bipiperidine (5g) in THF (50ml) under N₂ at 25°C was added 4-methylbenzenesulfonyl isocyanate (2.32ml) in THF (10ml) dropwise and the reaction stirred under N₂ at 25°C for 1 hour. 10M Aqueous sodium hydroxide (1.52ml) in water (50ml) was now added and the reaction stirred at 20°C for 18 hours. THF (60ml) was removed by distillation (reaction temperature 46-60°C, 500mbar), and the solution cooled to 35°C, giving precipitation. After stirring at 20°C for 18 hours the precipitate was filtered. The solid was dried (33°C, 25mbar) to give the title compound (7.07g).

NMR data consistent with Example 5.

Contains 8.3% w/w moisture by TGA.

25

EXAMPLE 9

This Example illustrates the preparation of the mono-sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide as Hydrate Form A.

To a solution of 4-(3,4-dichlorophenoxy)-1,4'-bipiperidine (5g) in THF (70ml) under N₂ at 25°C was added 4-methylbenzenesulfonyl isocyanate (2.33ml) in one portion. The reaction was stirred under N₂ at 25°C for 30 minutes. 10M Aqueous sodium hydroxide (1.52ml) in water (14ml) was now added and the reaction stirred for 2 hours. Further 10M aqueous sodium hydroxide (1.52ml) was now added and the reaction stirred

at 20°C for 20 hours. Solvent (50ml) was removed by distillation (1 bar) and the solution cooled to 20°C. Water (10ml) was added and the solution stirred for 18 hours giving precipitation. The mixture was filtered and dried (30°C, 9mbar) to give the title compound (5.35g).

5 NMR data consistent with Example 5.

Contains 3.5% w/w moisture by TGA; 3.8% w/w water content by Karl Fischer analysis.

XRPD of the product is presented in Figure 5. XRPD main reflection peaks are:

Reflection angle (°2θ)	D-spacing (Å)	Relative intensity (%)
4.3	20.6	84
4.9	18.0	34
8.5	10.3	52
12.8	6.9	35
14.8	6.0	30
15.6	5.7	29
16.7	5.3	36
17.5	5.1	40
17.7	5.0	38
18.4	4.8	30
19.9	4.5	33
20.6	4.3	100
22.1	4.0	33
22.6	3.9	41
23.3	3.8	70
24.1	3.7	32
24.5	3.6	30
25.1	3.5	33
29.2	3.1	37
29.9	3.0	36

EXAMPLE 10

This Example illustrates the preparation of the mono-sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide as Hydrate Form B.

5 To a solution of 4-(3,4-dichlorophenoxy)-1,4'-bipiperidine (5g) in THF (50ml) under N₂ at 25°C was added 4-methylbenzenesulfonyl isocyanate (2.33ml) in THF (20ml) dropwise and the reaction stirred under N₂ at 25°C for 15 minutes. 10M Aqueous sodium hydroxide (1.52ml) was then added and the reaction stirred for 24 hours. The precipitate that formed was filtered to leave a solid that was dried (40°C, 10-30mbar) to give the title
10 compound (7.04g; m.pt. 237°C).

¹H NMR δ (CD₃OD) 1.28 - 1.42 (2H, m), 1.70 - 1.82 (4H, m), 1.96 - 2.04 (2H, m), 2.35 (3H, s), 2.43 - 2.54 (3H, m), 2.56 - 2.66 (2H, m), 2.80 - 2.87 (2H, m), 4.34 - 4.42 (3H, m), 6.87 - 6.90 (1H, m), 7.09 - 7.10 (1H, m), 7.19 - 7.23 (2H, m), 7.35 - 7.38 (1H, m), 7.75 - 7.79 (2H, m). There is a large water peak at 4.87.

15 ¹³C NMR δ (CD₃OD) 21.4, 29.3, 31.6, 43.2, 47.2, 63.8, 74.5, 117.3, 119.1, 124.7, 128.0, 129.7, 132.1, 133.8, 142.0, 144.0, 158.3, 162.8.

Contains 6.52% w/w moisture by TGA; and 6.3% w/w water content by Karl Fischer analysis.

XRPD of the product is presented in Figure 6. XRPD main reflection peaks are:

Reflection angle (°2θ)	D-spacing (Å)	Relative intensity (%)
4.5	19.8	98
4.8	18.6	56
8.3	10.7	81
14.5	6.1	63
14.8	6.0	60
15.4	5.8	53
16.6	5.3	84
18.7	4.8	46
19.5	4.5	49
20.2	4.4	100
21.2	4.2	56
21.5	4.1	58

21.9	4.1	78
22.3	4.0	50
23.0	3.9	39
23.6	3.8	63
24.7	3.6	42
24.9	3.6	47
27.3	3.3	44
29.2	3.1	40

EXAMPLE 11

This Example illustrates the preparation of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide Form A.

- 5 4-(3,4-Dichlorophenoxy)-1,4'-bipiperidine (4.9 g) was dissolved in dichloromethane (50 ml). 4-Methylbenzenesulfonyl isocyanate (3.8ml) was added dropwise. The resulting solution was stirred for 1 hour then added to an SCX-2 column (50g SCX-2 resin; International Sorbent Technology Ltd) and eluted with methanol then methanol-aqueous ammonia (0.88 specific gravity; 9:1). The ammoniacal fractions were
10 evaporated and the residue was stirred with ether for 16 hours. The resultant solid was purified by flash chromatography (dichloromethane : 7M ammonia in methanol 6:1) followed by trituration with ether to give a solid. The solid was recrystallised from ethanol and then purified by RPHPLC (Xterra® column; 95:5 to 5:95 aq ammonia : MeCN). Product containing fractions were freeze-dried and then triturated with acetonitrile and
15 finally dried in vacuo at RT to give the title compound (3.1g; m.pt. 233-235°C).

¹H NMR δ (CD₃OD + NaOD) 1.27 - 1.39 (2H, m), 1.71 - 1.84 (4H, m), 1.97 - 2.03 (2H, m), 2.36 (3H, s), 2.44 - 2.52 (3H, m), 2.58 - 2.66 (2H, m), 2.79 - 2.85 (2H, m), 4.35 - 4.42 (3H, m), 6.88 (1H, dd), 7.08 (1H, d), 7.23 (2H, d), 7.37 (1H, d), 7.76 (2H, d).

No weight loss detected by TGA below melting point (243°C).

- 20 XRPD of the product is presented in Figure 7. XRPD main reflection peaks are:

Reflection angle (°2θ)	D-spacing (Å)	Relative intensity (%)
8.5	10.4	33
14.6	6.1	30
15.5	5.7	36

15.9	5.6	100
16.5	5.4	30
16.8	5.3	26
17.1	5.2	32
18.5	4.8	32
18.9	4.7	25
19.4	4.6	26
19.9	4.5	41
20.2	4.4	37
21.7	4.1	40
23.3	3.8	27
23.6	3.8	38
25.8	3.5	34
26.6	3.4	35
27.7	3.2	25
28.7	3.1	27
31.5	2.8	26

EXAMPLE 12

This Example illustrates the preparation of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide Form A.

- 5 To *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide Form B (see Example 13; 4.89g) was added acetonitrile (50ml) and the mixture heated to 50°C. Further acetonitrile (50ml) was added and the resultant slurry was stirred overnight at 50°C. The heater was then turned off and the flask allowed to cool to room temperature in the oil bath. The slurry was filtered and the resultant solid dried *in vacuo* overnight at 40°C to give the title compound (4.45g, 91%)

XRPD data consistent with Example 11.

EXAMPLE 13

- 15 This Example illustrates the preparation of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide Form B.

- 4-(3,4-Dichlorophenoxy)-1,4'-bipiperidine (5.0g) was dissolved in dichloromethane (40ml). 4-Methylbenzenesulfonyl isocyanate (3.3ml) was added dropwise. The mixture was stirred for 30 minutes and then water was added. The layers were separated and the organic phase was allowed to stand whilst product crystallised. The solid was collected, washed with dichloromethane and dried in vacuo at 40°C to give the title compound (6.2g; m.pt. 207-212°C).

- ¹H NMR δ(CD₃OD + NaOD): 1.27-1.40 (2H, m), 1.70 - 1.84 (4H, m), 1.96 - 2.05 (2H, m), 2.36 (3H, s), 2.44 - 2.52 (3H, m), 2.56 - 2.67 (2H, m), 2.79 - 2.86 (2H, m), 4.34 - 4.43 (3H, m), 6.88 (1H, dd), 7.09 (1H, d), 7.22 (2H, d), 7.37 (1H, d), 7.74 - 7.77 (2H, m)
- 10 Contains 0.11% w/w moisture by TGA.

XRPD of the product is presented in Figure 8. XRPD main reflection peaks are:

Reflection angle (°2θ)	D-spacing (Å)	Relative intensity (%)
5.4	16.5	67
5.8	15.3	64
9.9	9.0	43
10.5	8.5	50
11.0	8.0	76
11.6	7.6	75
13.3	6.7	71
13.9	6.4	60
14.9	5.9	79
16.3	5.4	53
17.3	5.1	62
18.0	4.9	70
19.0	4.7	77
20.3	4.4	100
21.5	4.1	69
22.2	4.0	96
23.0	3.9	80
23.2	3.8	77
23.9	3.7	65

EXAMPLE 14

This Example illustrates the preparation of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide Form B.

To a solution of 4-(3,4-dichlorophenoxy)-1,4'-bipiperidine (7.93g) in DCM (50ml) under N₂ at room temperature was added dropwise a solution of 4-methylbenzenesulfonyl isocyanate (3.68ml, 0.0241mol, 1eq) in DCM (25ml). The resultant solution was stirred at room temperature for three hours during which time precipitation occurred. The resultant solid was filtered and washed with DCM (80ml). The damp solid was dried *in vacuo* at 35°C overnight to give the title compound (9.63g, 76%).

XRPD data is consistent with the Example 13.

EXAMPLE 15

This Example illustrates the preparation of the mono-sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide as Hydrate Form C.

To the mono-sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide (2.93g, 4.87mmol) was added water (6ml) and acetone (24ml) and the resultant slurry heated to reflux to obtain a solution. The solution was allowed to cool to room temperature and then cooled further with ice/water. The resultant slurry was filtered and then dried *in vacuo* overnight at 35°C to give the title compound (1.96g, 67%).

¹H NMR δ (CD₃OD): 1.28 - 1.42 (2H, m), 1.70 - 1.82 (4H, m), 1.96 - 2.04 (2H, m), 2.35 (3H, s), 2.43 - 2.54 (3H, m), 2.56 - 2.66 (2H, m), 2.80 - 2.87 (2H, m), 4.34 - 4.42 (3H, m), 6.87 - 6.90 (1H, m), 7.09 - 7.10 (1H, m), 7.19 - 7.23 (2H, m), 7.35 - 7.38 (1H, m), 7.75 - 7.79 (2H, m); and a water peak at 4.87.

XRPD of the product is presented in Figure 9. XRPD main reflection peaks are: at 4.3° (±0.1°), 8.2° (±0.1°), 12.6° (±0.1°), 15.2° (±0.1°), 15.7° (±0.1°), 15.9° (±0.1°), 17.9° (±0.1°), 19.1° (±0.1°), 20.6° (±0.1°), 21.2° (±0.1°), 22.7° (±0.1°), and 24.7° (±0.1) 2θ.

EXAMPLE 16

Pharmacological Analysis: Calcium flux [Ca²⁺]_i assay

Human eosinophils

Human eosinophils were isolated from EDTA anticoagulated peripheral blood as previously described (Hansel et al., *J. Immunol. Methods*, 1991, 145, 105-110). The cells were resuspended ($5 \times 10^6 \text{ ml}^{-1}$) and loaded with $5 \mu\text{M}$ FLUO-3/AM + Pluronic F127 $2.2 \mu\text{l/ml}$ (Molecular Probes) in low potassium solution (LKS; NaCl 118mM, MgSO_4 0.8mM, glucose 5.5mM, Na_2CO_3 8.5mM, KCl 5mM, HEPES 20mM, CaCl_2 1.8mM, BSA 0.1%, pH 7.4) for one hour at room temperature. After loading, cells were centrifuged at 200g for 5min and resuspended in LKS at $2.5 \times 10^6 \text{ ml}^{-1}$. The cells were then transferred to 96 well FLIPr plates (Poly-D-Lysine plates from Becton Dickinson pre-incubated with $5 \mu\text{M}$ fibronectin for two hours) at $25 \mu\text{l/well}$. The plate was centrifuged at 200g for 5min and the cells were washed twice with LKS ($200 \mu\text{l}$; room temperature).

A compound of the Examples was pre-dissolved in DMSO and added to a final concentration of 0.1%(v/v) DMSO. Assays were initiated by the addition of an A_{50} concentration of eotaxin and the transient increase in fluo-3 fluorescence ($I_{\text{Ex}} = 490\text{nm}$ and $I_{\text{Em}} = 520\text{nm}$) monitored using a FLIPR (Fluorometric Imaging Plate Reader, Molecular Devices, Sunnyvale, U.S.A.).

Human eosinophil chemotaxis

Human eosinophils were isolated from EDTA anticoagulated peripheral blood as previously described (Hansel et al., *J. Immunol. Methods*, 1991, 145, 105-110). The cells were resuspended at $10 \times 10^6 \text{ ml}^{-1}$ in RPMI containing 200 IU/ml penicillin, $200 \mu\text{g/ml}$ streptomycin sulfate and supplemented with 10% HIFCS, at room temperature.

Eosinophils ($700 \mu\text{l}$) were pre-incubated for 15 mins at 37°C with $7 \mu\text{l}$ of either vehicle or compound (100x required final concentration in 10% DMSO). The chemotaxis plate (ChemoTx, $3 \mu\text{m}$ pore, Neuroprobe) was loaded by adding $28 \mu\text{l}$ of a concentration of eotaxin (0.1 to 100nM) containing a concentration of a compound according to the Examples or solvent to the lower wells of the chemotaxis plate. The filter was then placed over the wells and $25 \mu\text{l}$ of eosinophil suspension were added to the top of the filter. The plate was incubated for 1 hr at 37°C in a humidified incubator with a 95% air/5% CO_2 atmosphere to allow chemotaxis.

The medium, containing cells that had not migrated, was carefully aspirated from above the filter and discarded. The filter was washed once with phosphate buffered saline (PBS) containing 5 mM EDTA to remove any adherent cells. Cells that had migrated through the filter were pelleted by centrifugation ($300 \times g$ for 5 mins at room temperature)

and the filter removed and the supernatant transferred to each well of a 96-well plate (Costar). The pelleted cells were lysed by the addition of 28 μ l of PBS containing 0.5% Triton x100 followed by two cycles of freeze/thawing. The cell lysate was then added to the supernatant. The number of eosinophils migrating was quantified according to the method of Strath et al., *J. Immunol. Methods*, 1985, 83, 209 by measuring eosinophil peroxidase activity in the supernatant.

Compounds of the Examples were found to be antagonists of the eotaxin mediated human eosinophil chemotaxis.

EXAMPLE 17

Histamine H1 receptor binding activity of compounds of the invention was assessed by competition displacement of 1nM [3 H]-pyrilamine (Amersham, Bucks, Product code TRK 608, specific activity 30Ci/mmol) to 2 μ g membranes prepared from recombinant CHO-K1 cells expressing the human H1 receptor (Euroscreen SA, Brussels, Belgium, product code ES-390-M) in assay buffer (50mM Tris pH 7.4 containing 2mM MgCl₂, 250mM sucrose and 100mM NaCl) for 1 hour at room temperature.

Example	H1 pKi / [1328_S]
1	7.7

CLAIMS

1. An anhydrous form of mono-sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide (Anhydrous Form B)
5 having an X-ray powder diffraction pattern containing specific peaks at: 3.8° (±0.1°), 7.5° (±0.1°), 20.2° (±0.2°) and 22.5° (±0.1°) 2θ.
2. An anhydrous form of mono-sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide (Anhydrous Form C)
10 having an X-ray powder diffraction pattern containing specific peaks at: 4.4° (±0.1°), 8.3° (±0.1°), 14.5° (±0.1°), 16.6° (±0.1°), 20.2° (±0.1°), 21.1° (±0.1°) and 22.0° (±0.1°) 2θ.
3. A hydrated form of mono-sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide (Hydrate Form A)
15 having an X-ray powder diffraction pattern containing specific peaks at: 4.2° (±0.1°), 20.4° (±0.1°), 22.5° (±0.1°) and 23.2° (±0.1°) 2θ.
4. A compound as claimed in claim 3 wherein the water content is 3-8% w/w.
20
5. A hydrated form of mono-sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide (Hydrate Form B)
having an X-ray powder diffraction pattern containing specific peaks at: 4.5° (±0.1°), 8.3° (±0.1°), 14.5° (±0.1°), 16.6° (±0.1°), 20.2° (±0.1°), 21.9° (±0.1°) and
25 23.6° (±0.1°) 2θ.
6. A compound as claimed in claim 5 wherein the water content is 5-7% w/w.
7. A hydrated form of the sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide (Hydrate Form C)
30 having an X-ray powder diffraction pattern containing specific peaks at: 4.3° (±0.1°), 15.7° (±0.1°), 15.9° (±0.1°), 19.1° (±0.1°), 20.6° (±0.1°), and 21.1° (±0.1°) 2θ.


8. A crystalline form of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide (Form A) having an X-ray powder diffraction pattern containing specific peaks at: 15.5° (±0.1°), 15.9° (±0.1°), 19.9° (±0.1°), 20.2° (±0.1°), 21.7° (±0.1°), 25.8° (±0.1°) and 26.6° (±0.1°) 2θ.
9. A crystalline form of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide Form B having an X-ray powder diffraction pattern containing specific peaks at: 11.0° (±0.1°), 11.6° (±0.1°), 13.3° (±0.1°), 14.9° (±0.1°), 18.0° (±0.1°), 19.0° (±0.1°), 20.3° (±0.1°), 22.21° (±0.1°), 23.01° (±0.1°) and 23.21° (±0.1°) 2θ.
10. Processes for preparing the compounds as claimed in claims 1 to 9.
11. A pharmaceutical composition comprising a compound as claimed in claims 1 to 9 and a pharmaceutically acceptable adjuvant, diluent or carrier.
12. A compound as claimed in claims 1 to 9 for use in therapy.
13. The use of a compound as claimed in claims 1 to 9 in the manufacture of a medicament for use in therapy.
14. A method of treating a chemokine mediated disease state in a mammal suffering from, or at risk of, said disease, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound as claimed in claims 1 to 9.

ABSTRACT


CHEMICAL COMPOUNDS

The invention provides anhydrous and hydrated forms of mono-sodium salt of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide and crystalline forms of *N*-[[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl-benzenesulfonamide; and such compounds are modulators of chemokine (especially CCR3) activity and are especially useful for treating asthma and/or rhinitis.


1

FIGURE 1


5

FIGURE 2


2

FIGURE 3


5

FIGURE 4


3

FIGURE 5


5

FIGURE 6

4

FIGURE 7

5

FIGURE 8

5

FIGURE 9

